SUMMIT, N.J.--(BUSINESS WIRE)--
Celgene Corporation (NASDAQ:CELG) today announced the election of Mark
Alles and Jacqualyn Fouse PhD to its Board of Directors.
Mr. Alles has been with Celgene since 2004, most recently serving as
President and Chief Operating Officer (COO). Effective March 1, 2016,
Mr. Alles will be promoted to Chief Executive Officer, with Bob Hugin
assuming the Executive Chairman role. Before serving as President and
COO, Mr. Alles led Celgene's Hematology and Oncology franchise. Dr.
Fouse has been with Celgene since 2010, most recently serving as
President of Celgene's Hematology and Oncology franchise. Effective
March 1, 2016, Dr. Fouse will be promoted to President and COO. Before
serving as President of Celgene's Hematology and Oncology franchise, Dr.
Fouse served as Celgene's Chief Financial Officer.
"Mark and Jackie are extremely accomplished leaders who bring a wealth
of experience and judgment to our Board," said Bob Hugin, Chairman and
CEO of Celgene Corporation. "Their strategic vision and knowledge of our
business will be highly valued as we continue to guide Celgene's future."
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in the
discovery, development and commercialization of innovative therapies for
the treatment of cancer and inflammatory diseases through
next-generation solutions in protein homeostasis, immuno-oncology,
epigenetics, immunology and neuro-inflammation. For more information,
please visit www.celgene.com.
Follow Celgene on Social Media: @Celgene,
This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," "outlook" and
similar expressions. Forward-looking statements are based on
management's current plans, estimates, assumptions and projections, and
speak only as of the date they are made. We undertake no obligation to
update any forward-looking statement in light of new information or
future events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which are
difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual Report
on Form 10-K and our other reports filed with the Securities and
View source version on businesswire.com: http://www.businesswire.com/news/home/20160211005630/en/
Patrick E. Flanigan III, 908-673-9969
VP, Investor Relations
Brian Gill, 908-673-9530
Source: Celgene Corporation
News Provided by Acquire Media